12
Participants
Start Date
June 30, 1996
Primary Completion Date
May 31, 2008
Study Completion Date
May 31, 2008
Antineoplaston therapy (Atengenal + Astugenal)
Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
Burzynski Clinic, Houston
Lead Sponsor
Burzynski Research Institute
OTHER